13445-16-4

Usage

Uses

Used in Pharmaceutical Research and Development:
3-Bromo-2,6-dimethoxypyridine is used as a key intermediate in the synthesis of various pharmaceuticals for its potential therapeutic applications. Its unique structure allows for the development of new drugs with improved efficacy and reduced side effects.
Used in Organic Synthesis:
As a building block in organic synthesis, 3-Bromo-2,6-dimethoxypyridine is utilized for the preparation of a wide range of organic compounds, including complex molecules and functional materials.
Used in Agrochemical Production:
3-Bromo-2,6-dimethoxypyridine is employed as an intermediate in the production of agrochemicals, such as pesticides and herbicides, due to its ability to enhance the effectiveness of these products.
Used in Antimicrobial Applications:
3-Bromo-2,6-dimethoxypyridine is used as an antimicrobial agent, exhibiting activity against various microorganisms, including bacteria and fungi. Its incorporation into medical devices, coatings, or formulations can help prevent infections and promote overall health.
Used in Anticancer Research:
3-Bromo-2,6-dimethoxypyridine is used as a potential anticancer agent in research studies, exploring its ability to inhibit the growth and proliferation of cancer cells. Its antiproliferative properties make it a promising candidate for the development of novel cancer therapies.

InChI:InChI=1/C7H8BrNO2/c1-10-6-4-3-5(8)7(9-6)11-2/h3-4H,1-2H3

Upstream product

• 6231-18-1 2,6-dimethoxypyridine 

Downstream Products

• 229179-89-9 (R)-2,6-dimethoxy-3-(p-tolylsulfinyl)pyridine 
• 229179-88-8 (S)-2,6-dimethoxy-3-(p-tolylsulfinyl)pyridine 
• 357401-19-5 3-Bromo-2,6-dimethoxy-4-di(p-methylphenyl)phosphinopyridine 
• 220998-35-6 3-bromo-2,6-dimethoxy-4-diphenylphosphino-pyridine 
• 442686-31-9 4-[bis-(3,5-dimethyl-phenyl)-phosphanyl]-3-bromo-2,6-dimethoxy-pyridine 
• 214360-56-2 3-iodo-2,6-dimethoxypyridine 
• 158609-09-7 3-chloro-2,6-dimethoxypyridine 
• 1373693-68-5 2,6-dimethoxy-3-(phenylsulfanyl)pyridine 
• 221006-70-8 2,6-dimethoxypyridine-3-boronic acid 
• 885963-28-0 3-hydroxy-2,6-dimethoxypyridine 
• 1364917-21-4 2,3,6-trimethoxypyridine 

Relevant academic research and scientific papers

Catalyst-Free 1,2-Dibromination of Alkenes Using 1,3-Dibromo-5,5-dimethylhydantoin (DBDMH) as a Bromine Source

A direct 1,2-dibromination method of alkenes is realized using 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) as a bromine source. This reaction proceeds under mild reaction conditions without the use of a catalyst and an external oxidant. Various sorts of alkene substrates are transformed into the corresponding 1,2-dibrominated products in good to excellent yields with broad substrate scope and exclusive diastereoselectivity. This method offers a green and practical approach to synthesize vicinal dibromide compounds.

AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES

The present invention relates to novel ophthalmic devices comprising polymerized compounds comprising a photoactive chromophore, said polymerized compounds, and special monomer compounds being particularly suitable for compositions and ophthalmic devices. The present invention is also directed to a process of changing the optical properties of said ophthalmic device or a precursor article for manufacturing said ophthalmic device.

Directing Group Enables Electrochemical Selectively Meta-Bromination of Pyridines under Mild Conditions

Without the use of catalysts and oxidants, a facile and sustainable electrochemical bromination protocol was developed. By introducing the directing groups, the regioselectivity of pyridine derivatives could be controlled at themeta-position utilizing the inexpensive and safe bromine salts at room temperature. A variety of brominated pyridine derivatives were obtained in 28-95% yields, and the reaction could be readily performed at a gram scale. By combining the installation and removing the directing group, the concept ofmeta-bromination of pyridines could be verified.

Organic semiconductor photocatalyst can bifunctionalize arenes and heteroarenes

Photoexcited electron-hole pairs on a semiconductor surface can engage in redox reactions with two different substrates. Similar to conventional electrosynthesis, the primary redox intermediates afford only separate oxidized and reduced products or, more rarely, combine to one addition product. Here, we report that a stable organic semiconductor material, mesoporous graphitic carbon nitride (mpg-CN), can act as a visible-light photoredox catalyst to orchestrate oxidative and reductive interfacial electron transfers to two different substrates in a two- or three-component system for direct twofold carbon–hydrogen functionalization of arenes and heteroarenes. The mpg-CN catalyst tolerates reactive radicals and strong nucleophiles, is straightforwardly recoverable by simple centrifugation of reaction mixtures, and is reusable for at least four catalytic transformations with conserved activity.

Atom-Economic Electron Donors for Photobiocatalytic Halogenations

In vitro cofactor supply and regeneration have been a major obstacle for biocatalytic processes, in particular on a large scale. Peroxidases often suffer from inactivation by their oxidative co-factor. Combining photocatalysis and biocatalysis offers an innovative solution to this problem, but lacks atom economy due to the sacrificial electron donors needed. Herein, we show that redox-active buffers or even water alone can serve as efficient, biocompatible electron sources, when combined with photocatalysis. Mechanistic investigations revealed first insights into the possibilities and limitations of this approach and allowed adjusting the reaction conditions to the specific needs of biocatalytic transformations. Proof-of-concept for the applicability of this photobiocatalytic reaction setup was given by enzymatic halogenations.

New synthetic approaches towards analogues of bedaquiline

Multi-drug resistant tuberculosis (MDR-TB) is of growing global concern and threatens to undermine increasing efforts to control the worldwide spread of tuberculosis (TB). Bedaquiline has recently emerged as a new drug developed to specifically treat MDR-

ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES

Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral RNA polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration. Also disclosed are pharmaceutical compositions comprising one or more compounds mentioned above, or pharmaceutically acceptable salts thereof, as well as methods for preparing same. Also provided are methods for inhibiting viral RNA polymerase activity, viral replication, and treating viral infections.

Noncryogenic synthesis of functionalized 2-methoxypyridines by halogen-magnesium exchange using lithium dibutyl(isopropyl)magnesate(1-) and lithium chloride

2-Methoxypyridines functionalized in the 3-, 5-, or 6-position and 2,6-dimethoxypyridines functionalized in the 3-position were prepared from the corresponding bromo or iodo analogues by using lithium dibutyl(isopropyl) magnesate(1-) and lithium chloride

The preparation of 2,6-disubstituted pyridinyl phosphine oxides as novel anti-cancer agents

A series of 2,6-dimethoxylpyridinyl phosphine oxides have been synthesized and examined for their antitumor activity. 2,6-Dimethoxy-3-phenyl-4-diphenylphosphinoylpyridine 2 has been employed as the lead compound for this study. We found out that the prese

Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents

A series of azaheterocyclic carbazole sulfonamides was synthesized and evaluated for antiproliferative activity. The most potent compounds N-(2,6-dimethoxypyridine-3-yl)-9-ethyl and 9-methylcarbazole-3-sulfonamide (13 and 14) gave significant cytotoxicity (IC50 = 122 and 101 nM). Compound 13 displayed submicromolar activities against seven human tumor cell lines. The SARs of this series of sulfonamides which includes the influence of azaheterocycle rings, sulfonamide linkage, and the carbazole ring are described.